Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Prepaid Assets (2016 - 2025)

Sonoma Pharmaceuticals has reported Prepaid Assets over the past 15 years, most recently at $3.4 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 141.6% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, up 141.6%, while the annual FY2025 figure was $1.9 million, 1723.81% up from the prior year.
  • Prepaid Assets for Q4 2025 was $3.4 million at Sonoma Pharmaceuticals, up from $2.9 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $4.6 million in Q2 2023 and troughed at $25000.0 in Q1 2023.
  • A 5-year average of $2.8 million and a median of $3.2 million in 2021 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: crashed 95.97% in 2023 and later surged 1723.81% in 2025.
  • Year by year, Prepaid Assets stood at $3.2 million in 2021, then increased by 0.12% to $3.2 million in 2022, then rose by 24.12% to $4.0 million in 2023, then plummeted by 65.4% to $1.4 million in 2024, then skyrocketed by 141.6% to $3.4 million in 2025.
  • Business Quant data shows Prepaid Assets for SNOA at $3.4 million in Q4 2025, $2.9 million in Q3 2025, and $2.9 million in Q2 2025.